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Abstract
Objectives: We investigated and compared clinicopathologic features and subtype distribution of invasive breast
cancer among women <40 and ≥40 years of age.
Methods: We retrospectively compared clinicopathologic characteristics and subtype distribution of invasive breast
cancer in women <40 and ≥40 years of age, in a cohort of 1,130 patients. Subtypes included luminal A (positive for
hormone receptors [HR]—estrogen receptor [ER] and/or progesterone receptor [PR]—and negative for human
epidermal growth factor receptor 2 [HER2] with low Ki67), luminal B (HER2–) (HR+/HER2–/Ki67High), luminal B
(HER2+) (HR+/HER2+), HER2-overexpressing (HR–/HER2+), and triple negative (ER–/PR–/HER2–).
Results: Breast cancers in younger women had unfavorable clinicopathologic characteristics, including larger
tumors and more frequent node involvement. Subtypes among the 1,130 tumors were luminal A: 36.4%, luminal B
(HER2–): 35.0%, luminal B (HER2+): 7.5%, HER2-overexpressing: 7.1%, and triple negative: 14.0%. The age groups
significantly differed in subtype distribution (P<0.001). Luminal A subtype was more common in the older group
(38.5%) than the younger group (16.2%), and luminal B (HER2–) was more common in the younger group (52.2%)
than in the older group (33.2%; P<0.001).
Conclusions: Breast cancers in women younger than 40 years have unfavorable clinicopathologic characteristics
and are more likely to be luminal B (HER2–) and less likely to be luminal A than breast cancers in older women.
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Introduction
Breast cancer (BC) is the most common cause of malignancy-
associated death for women in many countries.1 Although
Japanese women have a lower incidence of BC than Western
women,2 it has been increasing in Japan.3 Women younger than
40 years of age have a lower BC incidence than older women, but
their BC incidence has been increasing.3
Moreover, BC in younger women has been shown to have
worse prognosis,4,5 although not all reports bear this out.6–8 In
general, tumors in younger patients are larger, are more likely to
have more lymph node involvement, and are less likely to have
favorable pathologic factors than those in older patients.9–11
Although younger age by itself has been suggested as a risk
factor, some studies indicate that age alone is not a poor
prognostic factor after adjusting for clinicopathologic factors.12,13
Recently, microarray-based technology has provided new
genetic approaches for investigating complex clinical issues
regarding BC outcomes.14,15 Remarkably, microarray studies have
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shown that BC is a heterogeneous collection of different
subtypes characterized by distinct aberrations at the molecular
level. Based on gene expression studies, BC can be classified into
at least five distinct subtypes: luminal A, luminal B, human
epidermal growth factor receptor 2 (HER2) overexpressing,
basal-like, and normal breast. Differences in gene expression
patterns have been associated with differences in clinical
outcomes.15 In general, the luminal A subtype is associated with
favorable outcomes whereas basal-like and HER2-overexpressing
subtypes have poor prognoses.14
Protein expression has been shown to act as a surrogate for
the tumor genomic profile when classifying BC into subtypes
with distinct clinical outcomes and biologic characteristics.16,17
Recently, subtype classification by protein expression rather than
molecular expression has become widely used because of its
greater convenience. The St. Gallen consensus statement
classifies BC subtypes by immunohistochemistry findings for
estrogen receptor (ER), progesterone receptor (PR) (together,
the hormone receptors [HR]), HER2, and Ki67 expression,18,19
into five major subtypes—luminal A (HR+/HER2–/Ki67Low),
luminal B (HER2–) (HR+/HER2–/Ki67High), luminal B (HER2+)
(HR+/HER2+), HER2-overexpressing (HR–/HER2+), and triple
negative (ER–/PR–/HER2–)—which we used in this study.
The relationship between BC subtype and age is not well
understood.10,12,20–23 We therefore compared clinicopathologic
characteristics and subtype distribution of invasive BC between
women older and younger than 40 years.
Advanced Publication by J-STAGE DOI https://doi.org/10.20407/fmj.2019-001




Between 2003 and 2014, 1,704 patients with BC were treated
at Fujita Health University Hospital. This study excluded men,
patients with stage IV, occult or noninvasive cancer, or bilateral
disease, and patients lost to follow-up immediately after surgery.
A total of 1,130 women with invasive BC were included. Patients
were divided into two groups: younger women (<40 years of age)
and older women (≥40 years of age). Histologic grades were
assessed according to the Bloom and Richardson classification
system.24 We investigated the relationship between clinico-
pathological factors (stage, T stage, pathological node status,
histological grade, PR status, subtype distribution, chemotherapy,
endocrine therapy, and types of operation) and the two age
groups. This retrospective study was approved by the Ethics
Committee of Fujita Health University (No. HM16-138).
Immunohistochemistry
Immunohistochemical methods were described previously.25
Although surgical specimens were used as sample sources, core
biopsies before neoadjuvant therapy were used for patients who
underwent neoadjuvant therapy. Immunohistochemical staining
was carried out using the SP1 and 1E2 (Ventana Medical, Tucson,
AZ, USA) staining systems for ER and PR, respectively. Positive
ER or PR status was defined as the presence of ≥1% positive
cancer cells. Immunohistochemical assays for HER2 were
performed using the Pathway anti-HER2/neu test (Ventana
Medical). Fluorescence in situ hybridization (FISH) was
performed using the PathVysion HER-2 DNA probe kit (Abbott
France SAS, Rungis, France). An immunohistochemistry score of
3+ or FISH amplification was defined as positive. Ki67 staining
was performed using the monoclonal antibody MIB-1 (Dako,
Glostrup, Denmark). The Ki67 labeling index was categorized as
low (<14%) or high (≥14%).26 All markers were assessed with
blinding to the clinical data.
Breast cancer subtype classification
Tumors were classified into five subtypes based on the status
of ER, PR, Ki67, and HER2 immunohistochemistry results:
luminal A (HR+/HER2–/Ki67Low), luminal B (HER2–) (HR+/
HER2–/Ki67High), luminal B (HER2+) (HR+/HER2+), HER2-
overexpressing (HR–/HER2+), and triple negative (ER–/PR–/
HER2–).
Distant disease-free and overall survival by age group
Distant disease-free survival (DDFS) was defined as first
distant recurrence or death from any cause. DDFS was calculated
from the date of diagnosis to the date of distant recurrence or
death. Overall survival (OS) was calculated from the date of
diagnosis to the date of death from any cause.27 We assessed
DDFS and OS in the two age groups.
Statistical analysis
Statistical analysis was performed using SPSS 22.0 software
(IBM Corp., Armonk, NY, USA). The chi-square test was used for
contingency table analysis. Survival curves were generated using
the Kaplan–Meier method.28 Survival comparisons were made
using the log-rank test.
Results
Clinical characteristics of study patients
Distribution of age at diagnosis of the 1,130 patients is shown
in Figure 1. Of the 1,130 patients, 111 (9.8%) were younger than
40 years and 1019 (90.2%) were older than 40 years. Table 1
shows their clinical profiles. Significantly more women in the
older group had early-stage (T1) BC (49.8%) than did the
younger women (37.8%; P=0.038).
Among the 1,130 patients, data on pathologic node status was
missing for 36 patients, including two younger women and 34
older women. Of the two young women, one did not undergo
axillary surgery. The remaining patient had no pathologic node
involvement after neoadjuvant chemotherapy (NAC) and showed
no evidence of negative lymph node status before NAC. Of the 34
older women with missing data, 28 patients did not undergo
axillary surgery; no information regarding pathologic node status
before NAC was available for six patients who underwent NAC.
Figure 1 Distribution of age at diagnosis among 1,130 patients.
Table 1 Breast tumor pathologic characteristics by age
Age group <40 years n=111 ≥40 years n=1019 Pn % n %
T stage
 T1 42 37.8% 507 49.8%
 T2 62 55.9% 423 41.5%
 T3  3  2.7%  36  3.5%
 T4  4  3.6%  53  5.2% 0.038
Pathological node status
 Negative 57 51.4% 633 62.2%
 Positive 52 46.8% 352 34.5%
 Unknown  2  1.8%  34  3.3% 0.032
Stage
 I 39 35.1% 476 46.7%
 IIA 46 41.5% 331 32.5%
 IIB 18 16.2% 122 12.0%
 IIIA  3  2.7%  31  3.0%
 IIIB  4  3.6%  49  4.8%
 IIC  1  0.9%  10  1.0% 0.209
Histological grade
 1 21 18.9% 291 28.6%
 2 57 51.4% 543 53.3%
 3 30 27.0% 155 15.2%
 Unknown  3  2.7%  30  2.9% 0.007
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In total, 34 older patients had missing node status. A significantly
higher percentage of the younger group (46.3%) had node
involvement than did the older group (34.5%; P=0.032).
A significantly higher percentage of younger women had
histologic grade 3 tumors (27.0%) than did the older women
(15.2%; P=0.007). No data were available about for three women
in the younger group and 30 in the older group.
Biologic markers and immunohistochemical BC subtype
The two age groups did not significantly differ in HR or HER2
status. Interestingly, however, a significantly larger percentage of
the younger group’s BCs were Ki67High (79.3% vs. 57.3%,
P<0.001).
Of the 1,130 tumors, 36.4% were luminal A, 35.0% were
luminal B (HER2–), 7.5% were luminal B (HER2+), 7.1% were
HER2-overexpressing, and 14.0% were triple negative. Their
distribution by age group significantly differed (P<0.001; Table
2). Luminal A subtype was more common in the older group
(38.5%) than the younger group (16.2%), whereas younger
women were more likely to have luminal B (HER2–) than older
women (52.2% vs. 33.2%).
Treatment options
The two age groups did not significantly differ in percentages
of patients treated with breast surgery or axillary surgery, or in
rates of hormonal therapy or anti-HER2 therapy (Table 3).
Chemotherapy was administered to 60.4% of the younger women
and 44.7% of the older women (P=0.002).
DDFS and OS by age group
Over an overall median follow-up of 5.10 years (range: 0.15–
12.59 years), DDFS and OS did not significantly differ between
the two age groups (Figure 2). The estimated five-year DDFS
rate was 89.8±1.1% for BC in older women and 87.3±3.5% in
younger women (P=0.273). The estimated five-year OS rate was
94.0±0.9% for older women and 93.8±2.5% for younger women
(P=0.775).
Discussion
The age-adjusted incidence rate of BC in Japanese women was
reportedly 79.7 per 100,000 women per year in 2009.29 In the
United States, it was 127.9 per 100,000 women per year in
2015.30 The peak age for BC is between 40 and 50 years in Asian
countries but between 60 and 70 years in Western countries.31 In
the United States, 6.6% of women with BC are diagnosed before
the age of 40 in 2008 according to the Surveillance, Epidemiology
and End Results database.32 In Japan, 7.7% of women with BC
diagnosed between 2004 and 2009 were younger than 40 years of
age according to Registration Committee of Japan Breast Cancer
Society.33 The cut-off age for “younger” BC patients varies in
different studies, although most investigations seem to use either
Table 2 Biological profiles and subtypes by age
Age group < 40 years ≥40 years Pn % n %
ER
 Negative 28 25.2% 227 22.3%
 Positive 83 74.8% 792 77.7% 0.480
PR
 Negative 37 33.3% 348 34.2%
 Positive 74 66.7% 671 65.8% 0.863
HER2
 Negative 94 84.7% 872 85.6%
 Positive 17 15.3% 147 14.4% 0.801
Ki67
 Low (<14 %) 23 20.7% 435 42.7%
 High (≥14 %) 88 79.3% 584 57.3% <0.001
Subtype
 Luminal A 18 16.2% 393 38.5%
 Luminal B (HER2–) 58 52.2% 338 33.2%
 Luminal B (HER2+) 10  9.0% 75  7.4%
 HER2 overexpressing  7  5.4%  73  7.2%
 Triple negative 18 16.2% 140 13.7% <0.001
ER: estrogen receptor; HER2: human epidermal growth factor receptor
2; PR: progesterone receptor.
Table 3 Treatment options by age
Age group <40 years n=111 ≥40 years n=1019 Pn % n %
Breast surgery
 No breast surgery  1  0.9%   1  0.1%
 Breast-conserving surgery 64 57.7% 606 59.5%
 Mastectomy 46 41.4% 563 40.4% 0.155
Axillary surgery
 No axillary surgery  1  0.9%  28  2.7%
 ALND±SNB 47 42.3% 393 38.6%
 SNB 63 56.8% 598 58.7% 0.415
Adjuvant and/or neoadjuvant chemotherapy
 Not given 44 39.6% 563 55.3%
 Given 67 60.4% 456 44.7% 0.002
Adjuvant and/or neoadjuvant endocrine therapy
 Not given 29 26.1% 223 21.9%
 Given 82 73.9% 796 78.1% 0.308
Adjuvant and/or neoadjuvant anti-HER2 therapy
 Not given 96 86.5% 908 89.1%
 Given 15 13.5% 111 10.9% 0.405
ALND: axillary lymph node dissection; HER2: human epidermal growth factor receptor 2; SNB: sentinel lymph node biopsy.
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the age of 35 or 40 years. In our study, 40 years was the cut-off
age. The incidence of invasive BC in our younger group was
9.8%, which is higher than results from other reports.32,33 This
may be because the distribution of age at diagnosis for BC differs
between Japan and the United States,31 or because study
participants had different background characteristics. Our study
excluded patients with stage IV, occult or noninvasive cancer, and
bilateral disease, but two previous studies included patients with
all types of BC.32,33
BC in younger women reportedly has a worse outcome than in
older women.4,5 However, this issue remains controversial.
According to a population-based study in Switzerland, relative
youthfulness did not affect survival.8 El-Saghir et al. also found
that younger age does not have any adverse effects on survival in
patients with BC.6 Moreover, a study by Chia et al. showed that
younger women with BC have a better prognosis than older
patients.7 A major reason for poor outcome in younger women is
thought to be stage shift or aggressive phenotype. In this study,
we examined clinical characteristics, subtypes, and clinical
outcomes of a retrospective cohort of patients in two age groups.
We found that breast tumors in younger women were larger,
more frequently node-positive, and more frequently of higher
histologic grade than those in older women. These findings are
consistent with results from previous studies.9–11 Stage
classification is based on the anatomical extent of cancer spread,
and is a critical prognostic factor. Smaller tumors are hard to find
in young patients because young women generally have dense
breasts on mammography. Moreover, in Japan, mammography
screening has been recommended biannually for women aged 40
years and over. It is a culturally accepted way to screen for BC
that is covered by national health insurance. Our finding that
older women had BCs diagnosed at earlier T stages compared
with those in younger women could be partially explained by the
mammography screening system for women aged 40 years and
over. As the incidence of BC in women younger than 40 years is
low and dense breasts make it more difficult to detect cancer
using a mammogram, our results do not support the idea of
lowering the age for routine mammography screening.
Conventionally, prediction of prognosis has been influenced by
the anatomical extent of the tumor, reflected by stage
classification, but tumor biology is apparently more relevant to
prognosis than tumor size.34 Currently, BC is widely recognized
as a heterogeneous group of different subtypes with varying
clinicopathologic features and response to systemic therapies.
Interestingly, we found that the luminal A subtype (usually
associated with better prognosis than other subtypes) was more
common among older women. By contrast, luminal B subtype,
(usually an aggressive phenotype) was more common among
younger women. These findings are consistent with the results
of Partridge et al.,23 but differ from the results of Morrison et al.20
The distribution of BC subtypes also differs among different
races.35 Variations in results among these studies might be
caused in part by different sample sizes or different races. We
don’t know why BC in young women was more likely to have
high Ki67 expression, which is a marker for proliferation. This
finding may be attributable to differences in plasma estradiol
levels between the two age groups. Estradiol has been shown to
enhance ER-induced proliferation of MCF-7 cells by stimulating
expression of Ki67.36 As our older group includes postmeno-
pausal women whose plasma estradiol levels are lower than
those of premenopausal women, the younger women group might
have higher Ki67 expression and a higher rate of luminal B
subtype compared with the older group. Histological grade is
decided by tubule formation, nuclear pleomorphism, and mitosis
count. As proliferation and mitosis are related, BC in younger
women might tend to have higher histologic grades than in older
women.
Surprisingly, our results did not indicate any significant
differences in DDFS or OS between the two age groups, even
though tumors in the younger women were larger, more
frequently had lymph node involvement, and were more likely to
have unfavorable pathologic factors than those in the older
women. Chemotherapy was used more frequently in the younger
women than in the older women. Our data seems consistent with
the finding that age is not a prognostic factor by van de Vijjver
et al.12 and Ibrahim et al.13 The reason why there were no
differences in outcomes between the two age groups in our study
might be related to the small sample size. Our study might have
lacked sufficient power to highlight the impact of outcomes.
Other reasons might be differences in chemotherapy rates in the
Figure 2 Distant disease-free and overall survival for 1,130 women with breast cancer. (A) Distant disease-free survival and (B) overall survival by age
group.
Clinicopathologic features and subtypes in young patients with breast cancer
4
two age groups or relative shorter follow up time for outcomes.
Our study has some limitations. First, this was a retrospective
study with data collected at a single institution. Accordingly, it
includes biases related to all retrospective studies, such as
selection bias. Second, the number of younger patients was
small. Because relatively small studies might not yield definitive
results, we must interpret the results with caution. A larger
observational series might provide additional data. However, our
study also contains several strengths. First, data on the two age
groups were precisely collected at a single institution. Second,
the relationship between BC subtype and age is now widely
thought to be an important topic in the field of BC.
In conclusion, BC in women younger than 40 years have
unfavorable clinicopathologic characteristics, and are more likely
to be luminal B (HER2–), and less likely to be the luminal A than
BCs in women older than 40 years. Further study with a larger
number of patients is recommended to validate our findings.
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